Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
73.45(c) 73.18(c) 72.11(c) 72.81(c) 71.97 Last
11 084 528 11 245 225 15 202 824 12 555 910 14 612 807 Volume
-0.50% -0.37% -1.46% +0.97% -1.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 46 894 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 15,9x
Yield 2021 3,56%
Sales 2022 50 687 M - -
Net income 2022 15 519 M - -
Net Debt 2022 10 724 M - -
P/E ratio 2022 12,4x
Yield 2022 3,86%
Capitalization 184 B 184 B -
EV / Sales 2021 4,26x
EV / Sales 2022 3,85x
Nbr of Employees 73 500
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MERCK & CO., INC.
10:57aSILVERBACK THERAPEUTICS : Reports Early Data From Phase 1/1b Study of SBT6050 in..
MT
10:27aHOOKIPA PHARMA : announces clinical collaboration with Merck & Co., Inc., Kenilw..
AQ
07:34aBIOXCEL THERAPEUTICS : Says Therapeutics Study Shows Anti-Tumor Activity of Pros..
MT
01:30aBIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone
CI
09/15HOOKIPA PHARMA : Merck Collaborate on Head, Neck Cancer Combo Therapy Developmen..
MT
09/15HOOKIPA Pharma Inc. Announces Clinical Collaboration with Merck & Co., Inc., ..
CI
09/15Hookipa Working With Merck in Advanced Head and Neck Cancers
DJ
09/14IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 ..
CI
09/14MERCK & CO., INC. : Ex-dividend day for
FA
09/13Merck sees potential U.S. authorization for COVID-19 antiviral before year-en..
RE
09/13MERCK & C : mpany CEO Expects Clinical Data on Covid Vaccine in H2 2021, Possibl..
MT
09/13MERCK : Cooley Continues Life Sciences Partnering Growth On East Coast
AQ
09/09Codexis, Inc. and Merck Amend and Extend License and Supply Agreement for Enz..
CI
09/09U.S. government to tackle Medicare drug payments to try to cut costs
RE
09/09PDS BIOTECHNOLOGY : Completes Recruitment in Safety Cohort of Phase 2 Study of H..
MT
More news
News in other languages on MERCK & CO., INC.
10:57aSilverback Therapeutics publie les premières données de l'étude de phase 1/1b..
09/13Merck envisage une autorisation potentielle aux États-Unis pour l'antiviral C..
09/09MÄRKTE USA/Wall Street von Spekulation über Geldpolitik gedrückt
09/09AKTIEN IM FOKUS : Pharmawerte weiter im Abwärtsstrudel - Biden-Pläne belasten
09/09PDS Biotechnology achève le recrutement de la cohorte de sécurité de l'étude ..
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 72,81 $
Average target price 94,61 $
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.99%184 309
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895